Overview

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Status:
Completed

Trial end date:
2021-01-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the long-term efficacy and safety of relugolix 40 milligrams (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for 28 weeks on heavy menstrual bleeding associated with uterine fibroids in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3001 or MVT-601-3002).

Phase:

Phase 3

Details

Lead Sponsor:

Myovant Sciences GmbH

Treatments:

Estradiol
Norethindrone
Norethindrone Acetate
Relugolix